Beam Therapeutics (NASDAQ:BEAM) Shares Up 5.5% After Analyst Upgrade

Beam Therapeutics Inc. (NASDAQ:BEAM)’s share price rose 5.5% during trading on Thursday after Citigroup raised their price target on the stock from $64.00 to $68.00. Citigroup currently has a buy rating on the stock. Beam Therapeutics traded as high as $24.46 and last traded at $24.3930. Approximately 513,977 shares were traded during trading, a decline of 74% from the average daily volume of 1,944,699 shares. The stock had previously closed at $23.12.

BEAM has been the subject of a number of other reports. Royal Bank Of Canada boosted their target price on shares of Beam Therapeutics from $22.00 to $26.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 25th. Wedbush raised their price target on shares of Beam Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen raised Beam Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Tudor Pickering set a $41.00 price objective on Beam Therapeutics in a research report on Wednesday, January 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $48.87.

Insider Activity at Beam Therapeutics

In other news, insider Christine Bellon sold 1,371 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $34.00, for a total value of $46,614.00. Following the sale, the insider owned 95,667 shares of the company’s stock, valued at approximately $3,252,678. The trade was a 1.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.50% of the company’s stock.

More Beam Therapeutics News

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Updated Phase 1/2 results show BEAM‑302 (60 mg) produced mean steady‑state total AAT of 16.1 µM (above the 11 µM protective threshold), corrected M‑AAT comprised ~94% of circulating AAT and mutant Z‑AAT fell ~84% — data the company says support a one‑time, disease‑modifying treatment and the move to pivotal development. GlobeNewswire Release
• Positive Sentiment: Beam says it will pursue an accelerated approval pathway per FDA feedback and expects to start a global pivotal cohort in H2 2026 — a faster regulatory path would materially de‑risk timing for a potential approval and commercial milestone realization. BioSpace Article
• Positive Sentiment: Sell‑side momentum: Citigroup raised its price target to $68 with a Buy rating (boosting upside expectations versus current levels), reflecting increased analyst conviction after the BEAM‑302 update. Benzinga (Citigroup note)
• Neutral Sentiment: Beam hosted an investor webcast to review the data and reiterate the 60 mg dose selection and development plan; management set expectations for enrolling ~50 additional patients for a pivotal expansion. Benzinga Clinical Update
• Neutral Sentiment: Market and analyst coverage is mixed but active — multiple firms maintain bullish long‑term targets (median target elevated vs. current price) which supports analyst‑driven flows but also reflects valuation dispersion. Zacks Summary
• Negative Sentiment: Safety watch: while single‑dose cohorts showed tolerability up to 75 mg, the small multi‑dose cohort had ALT/AST elevations (one Grade 4 ALT, Grade 3 AST) after a second dose — a safety signal that could complicate multi‑dose strategies or raise regulator questions. BioPharmaDive Coverage
• Negative Sentiment: Recent insider selling and large institutional portfolio trimming noted in data summaries may damp investor sentiment despite the clinical news; and the stock still trades below its 50‑day and 200‑day moving averages, which can limit near‑term technical momentum. Quiver Quant Summary

Institutional Investors Weigh In On Beam Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BEAM. Purpose Unlimited Inc. bought a new position in shares of Beam Therapeutics during the 4th quarter valued at about $80,000. Invesco Ltd. raised its holdings in shares of Beam Therapeutics by 20.5% in the 4th quarter. Invesco Ltd. now owns 213,185 shares of the company’s stock worth $5,909,000 after purchasing an additional 36,321 shares in the last quarter. Axxcess Wealth Management LLC bought a new stake in shares of Beam Therapeutics in the 4th quarter worth approximately $212,000. XTX Topco Ltd acquired a new stake in Beam Therapeutics during the fourth quarter valued at approximately $426,000. Finally, Virtus Investment Advisers LLC lifted its stake in Beam Therapeutics by 49.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 9,724 shares of the company’s stock valued at $270,000 after purchasing an additional 3,200 shares during the last quarter. 99.68% of the stock is currently owned by institutional investors.

Beam Therapeutics Price Performance

The stock has a market capitalization of $2.41 billion, a P/E ratio of -23.39 and a beta of 2.12. The stock’s fifty day moving average is $27.63 and its two-hundred day moving average is $26.26.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $3.46. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The company had revenue of $114.11 million for the quarter, compared to analysts’ expectations of $13.22 million. During the same quarter in the prior year, the company earned ($1.09) earnings per share. The firm’s revenue was up 280.3% on a year-over-year basis. Analysts expect that Beam Therapeutics Inc. will post -4.57 EPS for the current year.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.